相似文献
1
Design, Synthesis, and Optimization of Balanced Dual NK1/NK3 Receptor Antagonists.
ACS Med Chem Lett. 2014 Feb 13;5(5):550-5. doi: 10.1021/ml400528y. eCollection 2014 May 8.
2
Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia.
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6899-904. doi: 10.1016/j.bmcl.2011.07.116. Epub 2011 Aug 6.
3
Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.
Bioorg Med Chem Lett. 2014 Jan 15;24(2):510-4. doi: 10.1016/j.bmcl.2013.12.033. Epub 2013 Dec 15.
4
Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
Br J Pharmacol. 1997 Dec;122(8):1633-8. doi: 10.1038/sj.bjp.0701560.
5
Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
Bioorg Med Chem Lett. 2010 Jun 1;20(11):3405-8. doi: 10.1016/j.bmcl.2010.04.008. Epub 2010 Apr 9.
6
Further evidence for the involvement of tachykinin receptor subtypes in formalin and capsaicin models of pain in mice.
Neuropeptides. 1997 Aug;31(4):381-9. doi: 10.1016/s0143-4179(97)90075-5.
7
Neurokinin release in the rat nucleus of the solitary tract via NMDA and AMPA receptors.
Neuroscience. 2002;115(4):1023-33. doi: 10.1016/s0306-4522(02)00541-9.
8
The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.
Br J Pharmacol. 1995 Dec;116(8):3149-57. doi: 10.1111/j.1476-5381.1995.tb15117.x.
9
Distinct presynaptic control of dopamine release in striosomal- and matrix-enriched areas of the rat striatum by selective agonists of NK1, NK2, and NK3 tachykinin receptors.
Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11214-8. doi: 10.1073/pnas.89.23.11214.
10
In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists.
Br J Pharmacol. 1997 Oct;122(3):469-76. doi: 10.1038/sj.bjp.0701406.
引用本文的文献
1
CuH-Catalyzed Regio- and Enantioselective Hydrocarboxylation of Allenes: Toward Carboxylic Acids with Acyclic Quaternary Centers.
J Am Chem Soc. 2021 Apr 7;143(13):4935-4941. doi: 10.1021/jacs.1c01880. Epub 2021 Mar 24.
2
From receptor binding kinetics to signal transduction; a missing link in predicting in vivo drug-action.
Sci Rep. 2017 Oct 26;7(1):14169. doi: 10.1038/s41598-017-14257-4.
3
Synthesis and Fungicidal Activity of 1-(Carbamoylmethyl)-2-aryl-3,1-benzoxazines.
Molecules. 2017 Jul 6;22(7):1103. doi: 10.3390/molecules22071103.
本文引用的文献
1
Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.
Bioorg Med Chem Lett. 2014 Jan 15;24(2):510-4. doi: 10.1016/j.bmcl.2013.12.033. Epub 2013 Dec 15.
2
Multi-target drugs: the trend of drug research and development.
PLoS One. 2012;7(6):e40262. doi: 10.1371/journal.pone.0040262. Epub 2012 Jun 29.
3
Fragment-based approaches in drug discovery and chemical biology.
Biochemistry. 2012 Jun 26;51(25):4990-5003. doi: 10.1021/bi3005126. Epub 2012 Jun 14.
4
Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia.
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6899-904. doi: 10.1016/j.bmcl.2011.07.116. Epub 2011 Aug 6.
5
Enantioselective α-arylation of carbonyls via Cu(I)-bisoxazoline catalysis.
J Am Chem Soc. 2011 Sep 7;133(35):13782-5. doi: 10.1021/ja206050b. Epub 2011 Aug 17.
6
Enantioselective α-arylation of N-acyloxazolidinones with copper(II)-bisoxazoline catalysts and diaryliodonium salts.
J Am Chem Soc. 2011 Sep 7;133(35):13778-81. doi: 10.1021/ja206047h. Epub 2011 Aug 17.
7
Asymmetric alkyl-alkyl cross-couplings of unactivated secondary alkyl electrophiles: stereoconvergent Suzuki reactions of racemic acylated halohydrins.
J Am Chem Soc. 2010 Sep 1;132(34):11908-9. doi: 10.1021/ja105924f.
8
Asymmetric Suzuki cross-couplings of activated secondary alkyl electrophiles: arylations of racemic alpha-chloroamides.
J Am Chem Soc. 2010 Aug 18;132(32):11027-9. doi: 10.1021/ja105148g.
9
Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization.
Curr Pharm Des. 2010;16(28):3185-203. doi: 10.2174/138161210793292555.
10
Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
Bioorg Med Chem Lett. 2010 Jun 1;20(11):3405-8. doi: 10.1016/j.bmcl.2010.04.008. Epub 2010 Apr 9.
Zotero 插件